Stockscreener 앱 받기
2.81
19.07%
0.45
시간 외 거래:
2.90
0.09
+3.20%
전일 마감가:
$2.36
열려 있는:
$2.41
하루 거래량:
1.89M
Relative Volume:
1.18
시가총액:
$199.96M
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
-0.8515
EPS:
-3.3
순현금흐름:
$-167.04M
1주 성능:
+6.84%
1개월 성능:
+35.10%
6개월 성능:
+62.43%
1년 성능:
+41.92%
1일 변동 폭
$2.405
$2.88
1주일 범위
$2.36
$2.88
52주 변동 폭
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
명칭
Ventyx Biosciences Inc
전화
(858) 945-2393
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.81 | 180.04M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-03-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-11-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Wells Fargo | Overweight |
| 2022-12-19 | 개시 | Goldman | Buy |
| 2022-11-17 | 개시 | Morgan Stanley | Overweight |
| 2022-09-07 | 개시 | Stifel | Buy |
| 2022-09-01 | 개시 | H.C. Wainwright | Buy |
| 2022-05-09 | 개시 | Credit Suisse | Outperform |
| 2022-03-31 | 개시 | Canaccord Genuity | Buy |
| 2022-02-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-15 | 개시 | Jefferies | Buy |
| 2021-11-15 | 개시 | Piper Sandler | Overweight |
모두보기
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
What technical models suggest about Ventyx Biosciences Inc.’s comebackEntry Zone Watchlist With Momentum Focus - Newser
What MACD signals say about Ventyx Biosciences Inc.Free Weekly Watchlist of High Movers - Newser
Tools to monitor Ventyx Biosciences Inc. recovery probabilityFree Long Hold Safe Return Strategy - Newser
What recovery options are there for Ventyx Biosciences Inc.Free Real Trader Watchlist of Hot Stocks - Newser
Ventyx Biosciences Inc. stock chart pattern explainedSwing Trade Watchlist with Entry Zones - Newser
Has Ventyx Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewMomentum Screener with Buy and Sell Areas - Newser
A Quick Look at Today's Ratings for Ventyx Biosciences(VTYX.US), With a Forecast Between $9 to $21 - 富途牛牛
Ventyx Biosciences Earns Buy Rating: Analyst Cites Promising Developments - AInvest
Real time social sentiment graph for Ventyx Biosciences Inc.Chart Pattern Recognition for Profit Timing - Newser
Building trade automation scripts for Ventyx Biosciences Inc.Free Risk Adjusted Technical Entry Plan - Newser
Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to “Hold” - Defense World
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionFree Oversold Recovery Opportunity Stocks - Newser
Is Ventyx Biosciences Inc. forming a bottoming baseChart Scanner for Swing Trade Timing - Newser
Applying big data sentiment scoring on Ventyx Biosciences Inc.Entry Zone Watchlist With Momentum Focus - Newser
Ventyx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Smart tools for monitoring Ventyx Biosciences Inc.’s price actionDaily Market Momentum and Pressure Analysis - Newser
Ventyx Biosciences Q2 2025 Earnings Beat Estimates, Cash Position at $209M - AInvest
Ventyx (VTYX) Q2 Net Loss Drops 16% - The Globe and Mail
Ventyx Biosciences Q2 GAAP EPS of -$0.38 Beats Expectations - AInvest
Ventyx Biosciences Q2 FY25 Revenue $5.4mln, Cash Balance $209mln. - AInvest
Ventyx Breakthrough: Phase 2 Parkinson's Drug Shows Promise, Plus Two Major Trial Results Expected in Q4 2025 - Stock Titan
What candlestick patterns are forming on Ventyx Biosciences Inc.Free Accurate Buy Point for Momentum Stocks - Newser
Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday - Defense World
Options Data Show Bullish Bias in Ventyx Biosciences Inc.Watchlist for Low Risk High Return Stocks Updated - beatles.ru
Will Ventyx Biosciences Inc. Bounce From 52 Week LowChart Driven High Reward Trading Setup Presented - beatles.ru
Published on: 2025-08-04 01:54:41 - Newser
How many analysts rate Ventyx Biosciences Inc. as a “Buy”Consistently high returns - Jammu Links News
What are the latest earnings results for Ventyx Biosciences Inc.Invest in high-yield stocks with confidence - Jammu Links News
What makes Ventyx Biosciences Inc. stock price move sharplyInvest smarter with advanced market data - Jammu Links News
H.C. Wainwright Maintains Hold on Ventyx Biosciences Despite Quarterly Loss - AInvest
Datadog Exceeds Forecasts, Raises Guidance Amid Robust Growth and High Valuation - AInvest
What are analysts’ price targets for Ventyx Biosciences Inc. in the next 12 monthsUnprecedented market success - Jammu Links News
What analysts say about Ventyx Biosciences Inc. stockAchieve breakthrough performance with smart picks - Jammu Links News
Is it time to cut losses on Ventyx Biosciences Inc.Early Entry Ideas with Momentum Potential - newser.com
Analyzing Ventyx Biosciences Inc. with risk reward ratio chartsFree Breakout Entry Signal Confirmation Tool - Newser
Institutional scanner results for Ventyx Biosciences Inc.Buy and Hold Position Summary Review - Newser
Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Rises By 69,900.0% - Defense World
How to use Fibonacci retracement on Ventyx Biosciences Inc.Chart Risk Profile for Capital Preservation - Newser
Applying sector rotation models to Ventyx Biosciences Inc.Free Growth Based Investment Plan Guidance - Newser
Ventyx Biosciences Inc (VTYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):